Biotech stocks haven't seen much of a momentum thus far in the new year amid a lack of meaningful catalysts. The bygone week saw two FDA approvals:Â Horizon Therapeutics PLC's HZNP thyroid eye disorder drug and Epizyme Inc's EPZM tazemetostat for epithelioid sarcoma.
The Wuhan coronavirus scare triggered strong moves in stocks of companies working on treatment/vaccines for the deadly virus.
Here are the key catalysts that could impact trading in biotech stocks in the unfolding week.
Conferences
12th Annual T-cell Lymphoma Forum: Jan. 30–Feb. 1 in San Diego, California
PDUFA Dates
Aimmune Therapeutics Inc AIMT has a target action date of end of January for its peanut allergy treatment candidate Palforzia. An Adcom that evaluated the experimental therapy voted 7-to-2 in favor of the efficacy of Palforzia and 8-to-1 in favor of its safety.
See Also: 7 Blockbuster Drugs Expected To Be Launched In 2020
Clinical Readouts
Miragen Therapeutics Inc MGEN will make a poster presentation of data from the Phase 1 trial of cobomarsen, a miR inhibitor in patients with aggressive HTLV-1 Associated adult T-cell leukemia/lymphoma. The presentation is scheduled for Friday evening.
Earnings
Tuesday
- Pfizer Inc. PFE (before the market open)
Wednesday
- Illumina, Inc. ILMN (after the market close)
- Varian Medical Systems, Inc. VAR (after the market close)
- Hologic, Inc. HOLX
Thursday
- Quest Diagnostics Inc DGX (before the market open)
- Eli Lilly And Co LLY (before the market open)
- Biogen Inc BIIB (before the market open)
- Amgen, Inc. AMGN (after the market close)
- Edwards Lifesciences Corp EW (after the market close)
IPOs
Anpac Bio-Medical Science, which focuses on early cancer screening and detection, has filed to offer 17.50 million shares in an IPO, which is expected to be priced between $14 and $16. The company is seeking to list its shares on the Nasdaq under the ticker symbol "ANPC."
Arcutis Biotherapeutics, a biotech company developing topical therapies for common skin diseases, proposes to offer 7.8 million shares at a price range of $15-$17. The shares are to be listed on the Nasdaq under the ticker symbol "ARQT."
Black Diamond Therapeutics, a precision oncology company, is planning an 8.9-million share IPO to be priced between $16 and $18. The company expects to list the shares on the Nasdaq under the ticker symbol "BDTX."
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.